Lymphocyte Activation Gene 3 Protein, Pipeline Review, H2 2019 – Oncology, Cardiovascular, Ovarian Cancer, Hodgkin Lymphoma & Chronic Inflammation – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Lymphocyte Activation Gene 3 Protein – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Summary

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA class-II antigens.

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 34 molecules. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 5, 7, 1, 13, 5 and 1 respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Cardiovascular, Gastrointestinal and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Gastric Cancer, Adenocarcinoma Of The Gastroesophageal Junction, Diffuse Large B-Cell Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Melanoma, Triple-Negative Breast Cancer (TNBC), Cervical Cancer, Hepatocellular Carcinoma, Lymphoma, Ovarian Cancer, Small-Cell Lung Cancer, Colon Carcinoma, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Gastroesophageal (GE) Junction Carcinomas, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Malignant Mesothelioma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Renal Cell Carcinoma, Non-Hodgkin Lymphoma, Advanced Malignancy, Autoimmune Disorders, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Blood Cancer, Breast Cancer, Cardiovascular Disease, Chronic Inflammation, Chronic Lymphocytic Leukemia (CLL), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Inflammatory Bowel Disease, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Merkel Cell Carcinoma, Metastatic Ovarian Cancer, Metastatic Pancreatic Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Nasopharyngeal Cancer, Neuroendocrine Tumors, Peritoneal Cancer, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rheumatoid Arthritis, Soft Tissue Sarcoma and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

The latest report Lymphocyte Activation Gene 3 Protein – Pipeline Review, H2 2019, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development with respective active and dormant or discontinued projects.

Scope

• The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
• The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics and enlists all their major and minor projects
• The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

• Introduction
• Report Coverage
• Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Overview
• Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Therapeutics Development
• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Therapeutics Assessment
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Companies Involved in Therapeutics Development
• Abeome Corp
• Avacta Life Sciences Ltd
• BJ Bioscience Inc
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Co
• Crescendo Biologics Ltd
• Eli Lilly and Co
• F-star Biotechnology Ltd
• F. Hoffmann-La Roche Ltd
• Fountain Biopharma Inc
• GigaGen Inc
• GlaxoSmithKline Plc
• I-Mab Biopharma Co Ltd
• ILGEN Inc
• Immutep Ltd
• Incyte Corp
• Innovent Biologics Inc
• Leads Biolabs Inc
• Leidos Health
• Lipid Genomics Inc
• MacroGenics Inc
• Merck & Co Inc
• Novartis AG
• Regeneron Pharmaceuticals Inc
• Shanghai Henlius Biotech Inc
• Stcube Inc
• Sutro Biopharma Inc
• Symphogen A/S
• Xencor Inc
• Y-Biologics
• Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Drug Profiles
• (nivolumab + relatlimab) – Drug Profile
• AM-0003 – Drug Profile
• AVA-021 – Drug Profile
• Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Dormant Products
• Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Product Development Milestones
• Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9avjuh

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900